Targets › FFAR2
1 program from 1 company in 3 trials: 3 Phase 4; Neurology; next expected readout Jun 2029.
G protein-coupled receptor that is activated by a major product of dietary fiber digestion, the short chain fatty acids (SCFAs), and that plays a role in the regulation of whole-body energy homeostasis and in intestinal immunity. In omnivorous mammals, the short chain fatty acids acetate, propionate and butyrate are produced primarily by the gut microbiome that metabolizes dietary fibers. (UniProt, O15552)
Open in Phaseline: the race on FFAR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Green Valley (Shanghai) Pharmaceuticals | Sodium Oligomannate Capsules (GV-971) Modulator of gut microbiota and neuroinflammation | GLP1R, FFAR2 | Phase 4 | Alzheimer Disease; Alzheimer's Disease | Jun 2029 |
Alzheimer Disease (2) Alzheimer's Disease (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.